Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of T101 combined with nucleos(t)ide analogs in chronic hepatitis B
CTR20192316Phase 2Active
- Sponsor
- Transgene Tasly Biopharmaceutical
- Start
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TG1050 in Chronic Hepatitis B (CHB), sponsored by Transgene Tasly Biopharmaceutical. Started Dec 2019; status: active.
02
Drugs
TG1050
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20192316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192316.